Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853385 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 717
- Enrollment target
NCT00853385 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 717 participants.
The verdict
NCT00853385, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 717 participants
- Enrollment target
Study Summary
This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also included.
Interventions
- OTHER Placebo
- DRUG CP-690,550
- DRUG CP 690,550
- BIOLOGICAL Biologic TNFi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 717 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00853385
The ClinicalTrials.gov registry entry for NCT00853385 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 717 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00853385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00853385 about?
NCT00853385 is a clinical study titled "A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis". This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult pa...
What is the current status of trial NCT00853385?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 717 participants. The study started on 2009-05. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00853385?
The interventions under investigation include: Placebo (OTHER), CP-690,550 (DRUG), CP 690,550 (DRUG), Biologic TNFi (BIOLOGICAL).
Who is sponsoring clinical trial NCT00853385?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.